Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

Summary

To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.

Timeline

Start

2023-01-05

Primary completion

2026-02-03

Completion

2026-03-03

Drugs

Indications